Latest News

The investigation by BBC Panorama found that some restaurants listed on Just Eat were unable to provide information on the presence of allergens within the dishes when requested. As part of the investigation, the BBC also sent two dishes purchased

In 1993, Co-founder David Reading tragically lost his daughter Sarah at the young age of 17. She had not been previously diagnosed with a food allergy but was being treated for Asthma. Minutes after eating a dessert containing crushed peanuts,

05/12/2018 When considering everyday life with a severe allergy, you wouldn’t necessarily be aware of the impact this would have on routine tasks, such as playing football. Anaphylaxis Campaign Support Group Leader Tracey Dunn highlights the areas she has to

ITV news recently ran a report that uncovered an increase in the number of complaints raised about allergen labelling by food businesses. They wrote to every council in the UK asking them how many complaints they had received in the

November 2018 The Anaphylaxis Campaign is saddened to hear of the early and unexpected death of Professor Anthony J. Frew.  Professor Frew was a key opinion leader in allergen immunotherapy, with his research focusing on air pollution and on improving

On Monday 26th  November Lynne Regent, CEO of the Anaphylaxis Campaign attended a productive roundtable meeting with the Environment Secretary Michael Gove, the Food Minister David Rutley, specialists, industry stakeholders, academics and clinicians. Discussion focused on the review of allergen

Sonia Bagga, 39, went into anaphylactic shock after eating two bites of a chicken wrap that she didn’t know contained sesame seeds while on-board a BA flight returning home in September from a family holiday in Dubai. A doctor on

This project has been set up to provide a step-change in our understanding of food allergy in adulthood by determining its prevalence in the adult population.

The Anaphylaxis Campaign is delighted to hear about the success of Aimmune Therapeutics, Inc. Phase 3 PALISADE trial and publication of its results in the New England Journal of Medicine. PALISADE (Peanut Allergy oral Immunotherapy Study of AR101 for Desensitization, is an international, randomized (3:1),